Chord Energy heads into the final week of Q3 with a notable divergence: short sellers have been covering while options traders have swung decidedly more bullish, even as the stock has drifted 8% lower over the past month.
The short positioning story has shifted meaningfully. Short interest dropped 12% over the past week to 6.4% of the free float, reversing a mid-September build that briefly pushed the position above 4.2 million shares. The borrowing market reflects none of the tension a 6%-plus short position might imply: the cost to borrow runs at just 0.45%, and availability is loose at over 1,300%, meaning roughly 13 shares remain available to lend for every one already out on loan. That combination, a position that is actively shrinking with near-unlimited borrow supply, suggests shorts are exiting rather than pressing. The ORTEX short score has edged down to 46.9 from just under 50 a week ago, consistent with the broader cover move.
Options tell an even more directional story. The put/call ratio has dropped to 0.64, almost a full standard deviation below its 20-day average of 0.77, and well below the 52-week high of 0.95. A ratio this far below the recent norm reflects a clear tilt toward call buying, the least defensive options posture CHRD has seen in the past month. That shift coincides almost exactly with the period when short interest began falling on September 22 to 23, suggesting both markets are moving in the same direction.
The Street has been active and mostly constructive. Analyst targets have moved higher across the board in September, with Truist lifting to $180, UBS raising then trimming modestly to $184, Wells Fargo pushing to $175, and Stifel reinstating with a Buy and a $182 target. The mean price target stands near $173, implying roughly 29% upside to the current price of $134. That gap is also captured in the analyst recommendation differential factor score, which ranks in the 96th percentile of the ORTEX universe. The more cautious voices, Jefferies at a Hold but raising their target to $150, Citigroup similarly Neutral at $150, point to a stock where even the bears acknowledge the valuation case while remaining sceptical on execution. The EV/EBITDA multiple of 3.1x and a price/earnings of 7.9x underline why the value argument is hard to dismiss; the price-to-book has compressed to 0.82x. Dividend yield metrics and a dividend factor score of 87 add another layer to the value picture, though the most recent formal dividend records in the data predate the company's current form.
The bull case centres on CHRD's Williston Basin scale and its recent divestiture of non-operated Marcellus assets at an accretive price, which freed capital and sharpened focus on the Bakken. The bear case is the flip side: that concentration in a single basin leaves the company exposed to pipeline constraints and state-level regulatory risk, with FY27 production and capex both expected to step down as the Marcellus volumes exit the portfolio. Estimated adjusted EBITDAX and free cash flow projections have been trimmed accordingly. The 30-day decline in the price/earnings multiple of 1.5 turns reflects some of that concern being priced in. Among close peers, OVV and DVN posted flatter weeks, while SM and OXY both fell around 2% to 2.4%, suggesting the sector-wide drift is real rather than company-specific.
One data point worth noting on the ownership side: retail attention, as measured by Wikipedia page views and ORTEX stock-page traffic relative to the prior 90 days, posted a z-score of 2.1 around September 22. The timing aligns with the flurry of analyst activity mid-month, suggesting the Street's moves generated some broader interest. On the institutional side, BlackRock has grown its stake to nearly 13% of shares, and Invesco filed a fresh 13G in August at 5%, adding to a crowded but passive holder base. No 13D activist is on the register, and all large holders have filed as passive Schedule 13G filers.
Insider activity leans in the other direction. The company's own executives and directors sold a net $6.9 million worth of shares over the past 90 days, with CEO Daniel Brown selling roughly $1.6 million across two days in late August and director Samantha McKinney selling just over $1.4 million in early September. None of these trades were declared under 10b5-1 plans, though the volumes are not large relative to total holdings. The selling concentrated around prices of $135 to $152, which brackets the current level, making the current price a natural reference point for management's recent transactions.
Q3 earnings are due November 4. With 35 days to the print, the previous two quarterly reactions were modest: a 1% gain the day after the August 2026 print, and a 3.2% decline at the one before that. The question heading into November is less about whether the Bakken operations are running cleanly and more about what management signals on FY27 capital allocation as the Marcellus volumes formally roll off.
See the live data behind this article on ORTEX.
Open CHRD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
